Trefis says investors are watching whether MariTide's vomiting rate lands in the mid-20s or lower. Amgen also dropped an early obesity drug, AMG 513.
Recap by typeshit. Full story at Trefis.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
About 180 people will get MRI scans during food and money tasks through March 2027. Noom is funding the research led by neuroscientist Michael Platt.
Drugs may be considered for ages 10 to 19 only after supervised programs fail. WHO says GLP-1 evidence in children is still too thin.
Loading…